Apollon Wealth Management LLC Trims Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Apollon Wealth Management LLC decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,482 shares of the medical equipment provider’s stock after selling 392 shares during the period. Apollon Wealth Management LLC’s holdings in Zimmer Biomet were worth $226,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ZBH. Garde Capital Inc. purchased a new position in Zimmer Biomet in the first quarter worth approximately $29,000. Washington Trust Advisors Inc. acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at $30,000. Columbia River Financial Group LLC acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at $30,000. Accent Capital Management LLC purchased a new position in shares of Zimmer Biomet during the 1st quarter worth $35,000. Finally, Cullen Frost Bankers Inc. increased its position in shares of Zimmer Biomet by 1,452.4% during the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 305 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZBH. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a report on Friday, September 19th. BTIG Research lifted their price target on shares of Zimmer Biomet from $118.00 to $122.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Raymond James Financial increased their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Finally, Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $111.94.

Zimmer Biomet Stock Up 2.1%

Shares of NYSE ZBH opened at $102.00 on Friday. The stock has a market cap of $20.21 billion, a P/E ratio of 24.82, a PEG ratio of 2.35 and a beta of 0.67. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The business’s fifty day simple moving average is $101.74 and its 200-day simple moving average is $97.78.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet’s payout ratio is currently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 1.39% of the stock is owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.